Abstract
All new oral anticoagulants are direct specific reversible inhibitors, either direct factor Xa inhibitors or inhibitors of thrombin. The pharmacokinetic of the new drugs is mediated by P- glycoprotein (P-gp) and metabolised by liver enzymes for some of them, principally cytochrome P450. That explains an important risk of drug interactions. The particularity of these new drugs is a priori a pharmacokinetic and pharmacodynamic profile more predictable involving no need for laboratory monitoring. In some clinical situations (risk of too high or too low exposure), a specific dose is proposed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
